Inpefa (sotagliflozin)
Research Synopsis
- - Sotagliflozin, marketed as Inpefa, is a dual sodium-glucose transporter 1 and 2 (SGLT1/SGLT2) inhibitor, potentially beneficial for managing blood sugar levels in both Type 1 and Type 2 diabetes patients.
- - Recent studies indicate that sotagliflozin can improve glycemic control and may facilitate weight loss without significantly increasing the risk of hypoglycemia.
- - Research on sotagliflozin has shown promising results in type 1 diabetes models, where it improved blood glucose levels and allowed for reduced insulin dosages without increasing episodes of hypoglycemia.
- - In clinical studies for type 2 diabetes patients inadequately controlled with metformin, sotagliflozin displayed significant reductions in HbA1c levels and body weight, suggesting it is an effective adjunct therapy.
- - Adverse effects reported in studies of sotagliflozin are generally mild and similar to those seen in placebo groups, affirming its safety profile in various patient populations.
- - A particular focus in current research highlights sotagliflozin's ability to enhance postprandial glucose control by affecting glucose absorption in the intestinal tract, thus benefiting patients who have difficulties managing blood sugar spikes after meals.
- - The dual action of sotagliflozin on both SGLT1 and SGLT2 contributes to its effectiveness, allowing for a more comprehensive approach to managing diabetes by inducing glycosuria and lowering glucose levels systemically.
- - Ongoing research continues to explore the pharmacokinetics and therapeutic potential of sotagliflozin, including its interactions with other diabetes medications like DPP-4 inhibitors, to optimize diabetes management strategies.
- - There is a recognized need for further studies to fully understand the long-term benefits and risks of sotagliflozin, particularly in diverse populations and with respect to co-morbid conditions.
- - Overall, Inpefa (sotagliflozin) represents an innovative approach to diabetes treatment, emphasizing the importance of dual-target mechanisms in achieving better glycemic outcomes.
Inpefa (sotagliflozin)
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.
London, UK
2 hours ago
1 Received
- Some doctors suggest giving patients with a high bleeding risk a shorter treatment of medication after getting a special type of heart stent.
- This study looked at how safe and effective 1 month of this medication is compared to 3 months for patients who also had a type of heart problem or not.
- They found that 1-month treatment had the same chance of serious heart issues as the 3-month treatment, but it caused less bleeding after a year.
$100 - $150
Hourly Rate
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
London, UK
2 hours ago
1 Received
- A study involving 36 patients with type 2 diabetes mellitus (T2DM) tested the effects of the dual SGLT1/SGLT2 inhibitor LX4211 in different doses compared to a placebo over 28 days.
- LX4211 significantly improved key measures of blood sugar control, enhanced urinary glucose excretion, and decreased serum triglycerides, with potential benefits observed in weight and blood pressure.
- A follow-up study suggested LX4211 also boosts certain gut hormones, indicating its potential as a promising treatment strategy for T2DM without significant gastrointestinal side effects.
$100 - $150
Hourly Rate
Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
London, UK
2 hours ago
1 Received
- Combination therapy for type 2 diabetes may improve glycemic control by using sodium-dependent glucose transporter (SGLT)-1 inhibitors alongside DPP-4 inhibitors to enhance GLP-1 levels.
- A study compared the effects of LX4211 and sitagliptin, both individually and together, on various hormones and glucose levels in mice and patients with T2DM.
- Results showed a synergistic effect in mice and increased levels of active GLP-1 and PYY in the combination therapy group, suggesting this approach could be effective for managing diabetes.
$100 - $150
Hourly Rate
LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
London, UK
2 hours ago
1 Received
- LX4211 is a drug that inhibits two types of sodium/glucose cotransporters (SGLT1 and SGLT2), which helps lower blood sugar levels by reducing glucose absorption in the intestines and kidneys.
- In clinical trials for type 2 diabetes, LX4211 showed improvements in glycemic control and increased levels of hormones GLP-1 and PYY, which aid in managing blood sugar.
- Studies with genetically modified mice revealed that LX4211 enhances GLP-1 and PYY while decreasing GIP and blood sugar spikes, highlighting its unique effectiveness in managing diabetes through dual action on glucose transporters.
$100 - $150
Hourly Rate
Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.
London, UK
2 hours ago
1 Received
- SGLT1 and SGLT2 are key transporters for glucose absorption in the intestines and kidneys, respectively, and LX4211 is a new drug that inhibits both to lower glucose levels.
- The study involves a phase 2 clinical trial to assess LX4211's safety and effectiveness in type 2 diabetes patients who aren't well-controlled on metformin alone.
- The main goal is to measure changes in glycated hemoglobin A1c over 12 weeks, with secondary goals looking at fasting glucose, body weight, blood pressure, and safety concerns like hypoglycemia and GI issues.
$100 - $150
Hourly Rate
Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
London, UK
2 hours ago
1 Received
- LX4211 is a new medication that inhibits two glucose transporters, SGLT1 and SGLT2, which play key roles in glucose absorption and reabsorption in the body, impacting blood sugar levels and hormone release.
- The study aimed to find out how the timing of LX4211 doses in relation to meals affects its effectiveness on glucose levels and hormone release in twelve healthy participants.
- Results showed that taking LX4211 right before breakfast led to the best outcomes in controlling blood sugar and increasing beneficial hormones, with the treatment being well tolerated and no adverse effects like diarrhea reported.
$100 - $150
Hourly Rate
Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
London, UK
2 hours ago
1 Received
- The current treatment options for hyperglycemia in type 2 diabetes are limited and need improvement.
- A new approach involves inducing glycosuria, which helps lower glucose levels in the body.
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been found to be effective and safe compared to other oral diabetes medications, as shown in clinical trials.
$100 - $150
Hourly Rate
Effect of LX4211 on glucose homeostasis and body composition in preclinical models.
London, UK
2 hours ago
1 Received
- Treatments that lower blood glucose and body weight are beneficial for type 2 diabetes patients; LX4211 is a new oral medication that inhibits SGLT1 and SGLT2 to improve glycemic control and promote weight loss.
- * In preclinical studies, LX4211 effectively blocked glucose transport in various animal models and significantly increased urinary glucose excretion for over 24 hours.
- * Long-term treatment with LX4211 improved glucose levels and insulin response in diabetic mice, but some weight loss effects were countered by increased food intake in certain models, suggesting a complex relationship between the drug's effects and appetite.
$100 - $150
Hourly Rate
LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.
London, UK
2 hours ago
1 Received
- Study assessed LX4211, a drug targeting SGLT1 and SGLT2, for safety and effectiveness in type 2 diabetes patients with kidney issues.
- Thirty-one participants with low kidney function received either LX4211 or placebo for 7 days, measuring various glucose levels and other health markers.
- LX4211 significantly improved postprandial and fasting glucose levels, with positive effects on glucagon-like peptide 1 levels and urinary glucose excretion, suggesting it may benefit those with type 2 diabetes and renal impairment.
$100 - $150
Hourly Rate
Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.
London, UK
2 hours ago
1 Received
- - Sotagliflozin is an oral agent tested in type 1 diabetes (T1D) mice to enhance blood sugar control without increasing the risk of low blood sugar (hypoglycemia) by targeting kidney and intestinal glucose transport mechanisms.
- - In the study, various groups of T1D mice received different treatments, including low doses of insulin with or without sotagliflozin, and outcomes were measured through blood glucose and hemoglobin A1c (A1c) levels.
- - Results showed that sotagliflozin improved glycemic control in mice on low insulin without elevating hypoglycemia occurrences, making it a promising option for managing T1D.
$100 - $150
Hourly Rate
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
London, UK
2 hours ago
1 Received
- - SGLT2 inhibitors are a new class of diabetes medications aimed at selectively targeting the SGLT2 protein, which is important for managing blood sugar levels.
- - Recent research suggests that inhibiting SGLT1, another glucose transporter in the gut, could also be beneficial for diabetes treatment.
- - Sotagliflozin (LX4211) is a dual inhibitor of SGLT1 and SGLT2, offering unique benefits like improved blood sugar regulation after meals and may be effective for both type 1 and type 2 diabetes.
$100 - $150
Hourly Rate
Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
London, UK
2 hours ago
1 Received
- The study evaluated the effectiveness and safety of LX4211, a drug that inhibits SGLT1 and SGLT2, in type 2 diabetes patients who were not well-controlled on metformin.
- Participants were randomly assigned to different doses of LX4211 or a placebo, with the main goal of measuring changes in A1C levels after 12 weeks.
- Results showed that LX4211 significantly lowered A1C levels, reduced body weight and systolic blood pressure, and had mild side effects similar to placebo, making it a promising treatment option.
$100 - $150
Hourly Rate
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
London, UK
2 hours ago
1 Received
- - The study evaluated the safety and effectiveness of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as an additional treatment alongside insulin for patients with type 1 diabetes. - Results showed that patients taking sotagliflozin experienced a significant reduction in insulin dosage (32.1%) and improved glycemic control, with lower average daily glucose levels and HbA1c results compared to the placebo group. - Sotagliflozin also led to an increase in the time spent within the target glucose range and resulted in weight loss, without an increased risk of hypoglycemia.
$100 - $150
Hourly Rate
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
London, UK
2 hours ago
1 Received
- - The study examines how combining the SGLT2 inhibitor empagliflozin with the DPP-4 inhibitor linagliptin affects insulin sensitivity and glycemic control in db/db mice over 8 weeks.
- - Results showed that both empagliflozin alone and in combination with linagliptin improved blood sugar levels and insulin sensitivity, with changes in glucose disposal rates and gene expressions related to inflammation and metabolism.
- - These findings indicate that SGLT2 inhibition may enhance insulin sensitivity, offering a beneficial treatment strategy for type 2 diabetes patients facing insulin resistance.
$100 - $150
Hourly Rate
THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.
London, UK
2 hours ago
1 Received
- - The objective of this study was to review data on adjunctive therapies for type 1 diabetes (T1D), focusing on newer antihyperglycemic agents and their impact on hypoglycemia, obesity, mortality, and treatment goals.
- - The findings revealed that many T1D patients struggle to reach the standard glycated hemoglobin (A1C) goals, with challenges like hypoglycemia and rising obesity rates hindering effective insulin therapy; noninsulin drugs may help patients achieve better A1C levels with lower insulin dosages.
- - Promising results from pilot studies on SGLT2 inhibitors (dapagliflozin, empagliflozin) and GLP-1 receptor agonists (lirag
$100 - $150
Hourly Rate
Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
London, UK
2 hours ago
1 Received
- SGLT1 is crucial for absorbing glucose and galactose in the intestine, while SGLT2 helps reabsorb glucose in the kidneys; SGLT2 inhibitors promote glucose excretion in urine and offer benefits such as lower risk of hypoglycemia, weight loss, and effective management of type 2 diabetes (T2DM).
- Sotagliflozin (LX4211) is a pioneering dual SGLT1/SGLT2 inhibitor, aimed at improving glucose control in diabetes by also targeting intestinal glucose absorption, which helps reduce blood sugar levels after meals.
- Although it has a slightly weaker effect on glucose excretion compared to selective SGLT2 inhibitors, sotagliflozin is still
$100 - $150
Hourly Rate
Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA).
London, UK
2 hours ago
1 Received
- Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are serious diabetes emergencies, and their treatment varies significantly between the UK and USA.
- In the USA, DKA diagnosis relies on disease severity, while HHS is assessed based on total osmolality; the UK has distinct guidelines for each condition.
- There is a need for more research to create a unified approach to the diagnosis and treatment of DKA and HHS, given the existing overlap but notable differences in UK and USA practices.
$100 - $150
Hourly Rate
Hydrogen-bonded structures and interaction energies in two forms of the SGLT-2 inhibitor sotagliflozin.
London, UK
2 hours ago
1 Received
- The sotagliflozin molecule exists in two different forms: one as a pure crystal (form 1) and the other as a monohydrate (form 2) that includes water.
- Both forms feature layers held together by hydrogen bonds, which involve three hydroxyl (-OH) groups in their structure.
- The molecular interactions in these layers differ, with the non-hydrogen-bonded interactions in both forms having higher energy compared to the hydrogen-bonded pairs, and each layer has a different geometric arrangement or topology.
$100 - $150
Hourly Rate
Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.
London, UK
2 hours ago
1 Received
- * These drugs have become popular because they aid in weight loss and have a low risk of causing dangerously low blood sugar levels, while effectively managing glucose levels.
- * New research shows that SGLT2 inhibitors can also increase levels of glucagon-like peptide-1 (GLP-1), especially when taken with DPP4 inhibitors, suggesting they could be a promising treatment option for type 2 diabetes patients.
$100 - $150
Hourly Rate